Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1999-07-29
2004-06-08
Wehbe, Anne M. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S325000, C435S455000, C536S023500, C424S093600
Reexamination Certificate
active
06747013
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates generally to programmed cell death (apoptosis) and more specifically to the diagnosis and treatment of diseases of excess cellular accumulation due to defective apoptosis and more specifically to diagnosis and treatment of rheumatoid arthritis.
BACKGROUND OF THE INVENTION
Rheumatoid arthritis is a chronic inflammatory arthritis that afflicts approximately 1% of adults (Mitchell, D. 1985.
Rheumatoid Arthritis
. P D Utsinger, N.J. Zvaifler, G E Ehrlich, eds. J. B. Lippincott Co., Philadelphia, pp. 133-150). The distribution of affected joints is symmetric and typically involves the small articulations of the hands and feet, although the larger appendicular joints like the shoulders and hips are often affected in established disease. Joint deformities, including ulnar deviation of the metacarpal phalangeal joints of the hand or destruction of the weight bearing joints, can occur late in the disease.
The symptoms of the disease result from a massive increase in the number of cells lining the synovium of the joint. The various cell types which are present include type A synoviocytes, which have the characteristics of monocytes or terminally differentiated macrophages, and type B synoviocytes which are fibroblast-like. As these cells increase in number, the continuous inflammation causes initial symptoms. Eventually, local release of enzymes by the synovial internal lining degrade the extracellular matrix and cause deformity.
The mainstays of therapy for rheumatoid arthritis include non-steroidal anti-inflammatory drugs, injectable gold salts, immunosuppressive agents, and methotrexate. While controlled studies do show some clinical benefit from these drugs, improvement is often limited and toxicity is common. Furthermore, most data suggest that these agents do not halt the rate of cartilage or bone destruction. Hence, a novel treatment that is directed at the pathogenesis of the disease with potential disease modifying activity would be a major improvement. The origin of the cells in the hyperplastic synovial lining in chronic inflammatory joint diseases remains controversial.
Necrosis and apoptosis are two basic processes by which cells may die. In necrosis cell death usually is a result of cell injury. The cells tend to swell and lyse, and the cell contents ultimately spill into the extracellular space. By contrast, apoptosis is a mode of cell death in which single cells are deleted in the midst of living tissues. Apoptosis accounts for most of the programmed cell death (PCD) in tissue remodeling and for the cell loss that accompanies atrophy of adult tissues following withdrawal of endocrine and other growth stimuli. In addition, apoptosis is believed to be responsible for the physiologic death of cells in the course of normal tissue turnover (i.e., tissue homeostasis) (Kerr, J. F.,et al, 1972. Br.
J. Cancer
26:239-257; Wyllie, A. H., et al. 1980.
Int. Rev. Cytol.
68:251-306).
The effector mechanisms of apoptosis are only incompletely understood, but the nuclear changes which occur appear to be caused by the activation of endogenous calcium-magnesium-sensitive nucleases that cleave chromatin between nucleosomes and reduce the DNA of apoptotic cells. A number of regulators of apoptosis have been identified. Some of these are already familiar as protooncogenes and oncosuppressor genes, including c-myc, bcl-2, p53, and ras. The protooncogene products and oncosuppressor proteins are believed to control cellular susceptibility to apoptosis (Isaacs, J. T. 1994.
Curr. Opin. Oncol.
6:82-89). C-myc seems to determine whether cells continuously proliferate or enter apoptosis, depending on the availability of critical growth factors (Bisonnette, R. P., et al. 1994.
In Apoptosis II: The Molecular Basis of Apoptosis in Disease
. Cold Spring Harbor Laboratory Press). In cultured cells, expansion is usually determined by the presence of c-myc and growth factors, whereas apoptosis is seen when c-myc is present but growth factors are absent. Certain other oncogenes (e.g., ras and bcl-2) rescue cells from susceptibility to apoptosis. The oncosuppressor gene p53 is believed to initiate apoptosis by causing temporary G1/S arrest in cells expressing c-myc (Yonish-Rouach, et al.
Mol. Cell Biol.
13:1415-1423.).
SUMMARY OF THE INVENTION
The present invention is based on the seminal discovery that a causative agent of cellular accumulation in chronic inflammatory diseases is an insufficient level of apoptosis at the site of cellular accumulation. An insufficient level of apoptosis observed in these accumulation diseases correlates with the presence of altered or mutant polynucleotides or polypeptides known to be involved in apoptosis in the accumulating cells. Taken together, these findings indicate that the insufficient apoptosis among macrophages and fibroblast-like cells which causes the arthritis pathology or among other cells in chronic inflammatory diseases, is due to deficient apoptosis attributable to genes important in regulating apoptosis (e.g., p53).
Therefore, it is desirable to decrease the number of cells which may accumulate in chronic inflammatory disease by enhancing apoptosis at the site of increased cell number. Restoration of apoptosis may be accomplished by providing an apoptosis enhancing amount of functional or wild type gene, such as p53, to the tissues where cellular accumulation is occurring. Alternatively, specific therapy can provide a selective survival advantage only to cells that contain the wild type gene and gene product as opposed to a mutant or altered gene or gene product.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
REFERENCES:
patent: 5792751 (1998-08-01), Ledley et al.
patent: 6069134 (2000-05-01), Roth et al.
Li; et.al.; Adenovirus-mediated Bax Overexpression for the Induction of Therapeutic Apoptosis in Prostate Cancer, 2001, Cancer Research 61: 186-191.*
Ledley F., “Pharmaceutical Approach to Somatic Gene Therapy.” Pharmaceutical Res., vol. 13: 1595-1613, Nov. 1996.*
Eck et al., “Gene-based therapy.” Goodman & Gilman's The Pharmacological Basis of Therapeutics-Ninth Edition. McGraw-Hill: 77-101, 1996.*
Orkin et al., “Report and recommendations of the panel to assess the NIH investment in research on gene therapy.” pp. 1-20, Dec. 1995.*
Miller et al., “Targeted vectors for gene therapy.” FASEB Journal, vol. 9: 190-199, Feb. 1995.*
Verma et al., “Gene therapy-promises, problems and prospects.” Nature vol. 389 : 239-242, Sep. 1997.*
W. French Anderson, “Human gene therapy.” Nature vol. 392 Supp : 25-30, Apr. 1998.*
Vaux et al., “The molecular biology of apoptosis.” Proc. Natl. Acad. Sci. USA vol. 93 : 2239-2244, Mar. 1996.*
Kumar et al., “Role of multiple cellular proteases in the execution of programmed cell death.” FEBS Letters 375: 169-173, 1995.*
Bandara et al., “Gene Transfer to Synoviocytes: Prospects for Gene Treatment of Arthritis”,DNA and Cell Biology, 1992, vol. 11, No. 3, pp. 227-231.
Roessler et al., “Adenoviral-mediated Gene Transfer to Rabbit Synovium in Vivo”,Journal of Clinical Investigation, Aug., 1993, vol. 92, pp. 1085-1092.
Firestein et al., “Apoptosis in Rheumatoid Arthritis Synovium”,Arthritis and Rheumatism, Abstracts of Scientific Presentations, Sep. 1994, vol. 37, No. 9 (Supplement), p. S311, Abstract 899.
Markarov et al., Gene Ther (Aug. 1995), 2(6):424-428.
Nita et al., Arthritis Rheum (May 1996), 39(5):820-828.
Ghivizzani et al., Gene Ther (Sep. 1997), 4(9):977-982.
Nguyen et al., J Rheumatol (Jun. 1998), 25(6):1118-1125.
Bandara et al., Proc Natl Acad Sci USA (Nov. 1993), 90(22):10764-10768.
Hung et al., Gene Ther (Jan. 1994), 1(1):64-69.
Evans et al., Hum Gene Ther (Jun. 1996), 7(10):1261-1280.
Muller-Ladner et al., (Apr. 1997), 158(7):3492-2498.
Bakker et al., Arthritis Rheum (May 1997), 40(5):893-900.
Chernajovsky et al., Gene Ther (Jun. 1997), 4(6):553-559.
Le et al., Arthritis Rheum (Sep. 1997), 40(9):1662-1669.
Bessis et al., Clin Exp Immunol (Feb. 1998)
Firestein Gary S.
Green Douglas R.
Zvaifler Nathan J.
Gray Cary Ware & Freidenrich LLP
The Regents of the University of California
Wehbe Anne M.
LandOfFree
Therapy for cellular accumulation in chronic inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapy for cellular accumulation in chronic inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy for cellular accumulation in chronic inflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3336778